Literature DB >> 29723416

The evolution of dasatinib dosage over the years and its relevance to other anticancer medications.

Charles A Schiffer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29723416      PMCID： PMC6860021          DOI： 10.1002/cncr.31516

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  13 in total

1.  First-line treatment for patients with CML in chronic phase: why imatinib is an appropriate choice.

Authors:  Charles A Schiffer
Journal:  Oncology (Williston Park)       Date:  2013-08       Impact factor: 2.990

2.  Ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Moshe Talpaz; Hagop Kantarjian
Journal:  N Engl J Med       Date:  2014-02-06       Impact factor: 91.245

3.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Kiran Naqvi; Elias Jabbour; Jeffrey Skinner; Musa Yilmaz; Alessandra Ferrajoli; Prithviraj Bose; Philip Thompson; Yesid Alvarado; Nitin Jain; Koichi Takahashi; Jan Burger; Zeev Estrov; Gautam Borthakur; Naveen Pemmaraju; Shilpa Paul; Jorge Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2018-05-03       Impact factor: 6.860

5.  Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.

Authors:  Domenico Russo; Giovanni Martinelli; Michele Malagola; Cristina Skert; Simona Soverini; Ilaria Iacobucci; Antonio De Vivo; Nicoletta Testoni; Fausto Castagnetti; Gabriele Gugliotta; Diamante Turri; Micaela Bergamaschi; Michela Bergamaschi; Patrizia Pregno; Ester Pungolino; Fabio Stagno; Massimo Breccia; Bruno Martino; Tamara Intermesoli; Carmen Fava; Elisabetta Abruzzese; Mario Tiribelli; Catia Bigazzi; Bruno Mario Cesana; Gianantonio Rosti; Michele Baccarani
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

6.  A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Jerald P Radich; Kenneth J Kopecky; Frederick R Appelbaum; Suzanne Kamel-Reid; Wendy Stock; Greg Malnassy; Elisabeth Paietta; Martha Wadleigh; Richard A Larson; Peter Emanuel; Martin Tallman; Jeff Lipton; A Robert Turner; Michael Deininger; Brian J Druker
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

7.  Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Authors:  Jorge E Cortes; Giuseppe Saglio; Hagop M Kantarjian; Michele Baccarani; Jiří Mayer; Concepción Boqué; Neil P Shah; Charles Chuah; Luis Casanova; Brigid Bradley-Garelik; George Manos; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

8.  Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

Authors:  A Hochhaus; G Saglio; T P Hughes; R A Larson; D-W Kim; S Issaragrisil; P D le Coutre; G Etienne; P E Dorlhiac-Llacer; R E Clark; I W Flinn; H Nakamae; B Donohue; W Deng; D Dalal; H D Menssen; H M Kantarjian
Journal:  Leukemia       Date:  2016-02-03       Impact factor: 11.528

9.  Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

Authors:  Neil P Shah; Philippe Rousselot; Charles Schiffer; Delphine Rea; Jorge E Cortes; Jorge Milone; Hesham Mohamed; Diane Healey; Hagop Kantarjian; Andreas Hochhaus; Giuseppe Saglio
Journal:  Am J Hematol       Date:  2016-06-20       Impact factor: 10.047

10.  Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.

Authors:  Charles A Schiffer; Jorge E Cortes; Andreas Hochhaus; Giuseppe Saglio; Philipp le Coutre; Kimmo Porkka; Satu Mustjoki; Hesham Mohamed; Neil P Shah
Journal:  Cancer       Date:  2016-03-21       Impact factor: 6.860
View more
  1 in total

1.  To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia.

Authors:  Joshua T Schiffer; Charles A Schiffer
Journal:  Haematologica       Date:  2018-11       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.